Screener
Xeris Biopharma Holdings, Inc. XERS Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net loss before income taxes | (31,101) | (1,928) | (28,867) | (11,148) |
| Income tax benefit | — | — | — | — |
| Net loss | $(31,101) | $(1,928) | $(28,867) | $(11,148) |
| Other comprehensive income (loss), net of tax: | ||||
| Foreign currency translation adjustments | 14 | 1 | 15 | 1 |
| Comprehensive loss | $(31,087) | $(1,927) | $(28,852) | $(11,147) |
| Net loss per common share - basic and diluted | $(0.18) | $(0.01) | $(0.17) | $(0.07) |
| Weighted average common shares outstanding - basic and diluted | 172,823,455 | 159,459,413 | 171,679,686 | 155,972,048 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Xeris Biopharma Holdings, Inc. (XERS) reported comprehensive income (loss), net of tax, attributable to parent of -$31.09M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 1513.2% year-over-year, from -$1.93M to -$31.09M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a -74.1% compound annual growth rate (CAGR), from -$122.76M to $554K.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity resulting from both net income and other comprehensive income items, such as unrealized gains or losses on securities and foreign currency translation adjustments. It provides a holistic view of the company's financial performance by incorporating non-operating gains and losses that bypass the traditional income statement. Investors use this to assess the total impact of all financial activities on the company's net worth.
Ask your AI about Xeris Biopharma Holdings, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude